within Pharmacolibrary.Drugs.ATC.C;

model C09DA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.37 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 16 / 1000000,
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 1800
  );

  annotation(Documentation(
    info ="<html><body><p>Candesartan and diuretics are a combination therapy typically used for the treatment of hypertension and heart failure. Candesartan is an angiotensin II receptor blocker (ARB), while the diuretic component (commonly hydrochlorothiazide) enhances sodium and water excretion. This combination is approved and widely used for blood pressure control, especially in patients not adequately managed by monotherapy.</p><h4>Pharmacokinetics</h4><p>No direct published pharmacokinetic model for the fixed combination C09DA06 is available. Estimates are based on available literature of candesartan cilexetil with hydrochlorothiazide in healthy adults.</p><h4>References</h4><ol><li><p>Bharathi, DV, et al., &amp; Venkateswarlu, V (2012). LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. <i>Bioanalysis</i> 4(10) 1195–1204. DOI:<a href=&quot;https://doi.org/10.4155/bio.12.83&quot;>10.4155/bio.12.83</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22651563/&quot;>https://pubmed.ncbi.nlm.nih.gov/22651563</a></p></li><li><p>Pandey, AK, et al., &amp; Malhotra, S (2020). Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. <i>Journal of hypertension</i> 38(8) 1593–1602. DOI:<a href=&quot;https://doi.org/10.1097/HJH.0000000000002429&quot;>10.1097/HJH.0000000000002429</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32371763/&quot;>https://pubmed.ncbi.nlm.nih.gov/32371763</a></p></li><li><p>McClellan, KJ, &amp; Jarvis, B (2000). Lercanidipine: a review of its use in hypertension. <i>Drugs</i> 60(5) 1123–1140. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200060050-00009&quot;>10.2165/00003495-200060050-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11129125/&quot;>https://pubmed.ncbi.nlm.nih.gov/11129125</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09DA06;
